Dr. Michael Perry

Biography

Dr. Perry has served as a member of Company’s board of directors since November 2005.  Since June 2017, Dr. Perry has served as the CEO of Avita Medical. From 2014 – 2017, Dr. Perry served as Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit and from 2012 – 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp., a US affiliate of Switzerland-based Novartis AG.  Dr. Perry has previously served as the Global Head of R&D at Baxter Healthcare, President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc., VP Regulatory Affairs at Sandoz Pharmaceuticals Corp., Director of Regulatory Affairs at Schering-Plough Corporation, and Chairman, CEO or CMO at several early stage biotech companies.  He also previously served as a Venture Partner with Bay City Capital, LLC based in San Francisco California. He also serves as a member of the board of Arrowhead Research Corporation and of Avita Medical Ltd. Dr. Perry holds a Doctor of Veterinary Medicine, a Ph.D. in Biomedical Science - Cardiopulmonary Pharmacology and a B.S. in Physics from the University of Guelph.

Research Interest

  Pharmaceutics & Biopharmaceutics Drug Targeting & Drug Development Pharmaceutical Research Pharmaceutical Materials Pharmaceutical Formulations Pharmaceutical Biotechnology Pharmaceutical Nanotechnology Pharmaceutical Technology Pharmaceutical Manufacturing Pharmaceutical Engineering Drug Delivery Technologies Medical Devices Drug Regulatory Affairs Pharmaceutical Management